SAB Biotherapeutics (SABS) Fundamental Analysis: Revenue, Earnings & Valuation

4.65 / 10

Netural

Corporate fundamentals rate average at 4.7/10. Beneficial factors: Asset-MV and Net income-Revenue, whereas limitations surface in Net cash flow from operating activities per share (YoY growth rate %) and Gross profit margin (%). Resultant assessment: guarded.

Analysis Checks(7/10)

Revenue-MV

Value-0.18

Score1/3

Weight5.45%

1M Return1.90%

Net cash flow from operating activities per share (YoY growth rate %)

Value74.53

Score1/3

Weight-0.18%

1M Return-0.07%

Total operating revenue (YoY growth rate %)

Value-100.00

Score3/3

Weight4.81%

1M Return1.78%

Inventory turnover ratio

Value98.02

Score3/3

Weight14.61%

1M Return4.88%

Gross profit margin (%)

Value35.29

Score1/3

Weight-0.47%

1M Return-0.19%

Net income-Revenue

Value-0.05

Score2/3

Weight11.28%

1M Return3.85%

Current assets turnover ratio

Value0.00

Score2/3

Weight3.38%

1M Return1.32%

Cost of sales ratio (%)

Value71.87

Score3/3

Weight12.61%

1M Return4.41%

Asset-MV

Value-0.49

Score2/3

Weight37.35%

1M Return11.52%

Cash-MV

Value0.01

Score2/3

Weight11.15%

1M Return3.76%

Is SABS fundamentally strong?

SABS scores 4.65/10 on fundamentals and holds a Fair valuation at present. Backed by its 14.96% ROE, 0.00% net margin, 20.54 P/E ratio, 1.80 P/B ratio, and 105.98% earnings growth, these metrics solidify its Netural investment rating.